Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Fate Therapeutics Inc (NASDAQ:FATE)

4.07
Delayed Data
As of Feb 24
 +0.05 / +1.24%
Today’s Change
1.47
Today|||52-Week Range
4.75
+62.15%
Year-to-Date

Today’s Trading

Previous close4.02
Today’s open4.02
Day’s range3.85 - 4.10
Volume307,176
Average volume (3 months)199,196
Market cap$168.4M
Dividend yield--
Data as of 4:00pm ET, 02/24/2017

Growth & Valuation

Earnings growth (last year)+7.09%
Earnings growth (this year)+3.67%
Earnings growth (next 5 years)--
Revenue growth (last year)--
P/E ratioNM
Price/Sales35.33
Price/Book3.07

Competitors

 Today’s
change
Today’s
% change
PFNXPfenex Inc-0.27-3.65%
ASTAsterias Biotherapeu...-0.10-2.63%
CBMGCellular Biomedicine...-0.20-1.71%
KDMNKadmon Holdings Inc-0.08-2.18%
Data as of 4:04pm ET, 02/24/2017

Financials

Next reporting dateMarch 9, 2017
EPS forecast (this quarter)-$0.28
Annual revenue (last year)$2.4M
Annual profit (last year)-$30.0M
Net profit margin-1,233.73%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
J. Scott Wolchko
Chief Scientific Officer
Daniel D. Shoemaker
Corporate headquarters
San Diego, California

Forecasts


Search for Jobs